Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
Status:
Recruiting
Trial end date:
2021-12-04
Target enrollment:
Participant gender:
Summary
The study is to estimate the effect of hepatic impairment on the plasma PK of
PF-07321332/ritonavir. Findings from this study will be used to develop dosing
recommendations so that the dose and/or dosing interval may be adjusted appropriately in the
presence of hepatic impairment.